Faron Pharmaceuticals Oy Share Discussion Threads

[bwgs] 18/1/2021 08:29

Yes, great update !

[cwebb07] 18/1/2021 08:06

US ministry of defence giving $6m grant for Traumakine.Things looker much stronger now

[sharesoc] 17/11/2020 12:33

The presentation packs and recording from our webinar with Faron Pharma on 3rd Nov can be found here for full members to view:

To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc.org/membership/

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc.org/contact-us/

[soulected] 27/10/2020 10:10

Interesting new Proactive video, confirming that Traumakine (interferon IV) has not yet been tested for Covid and results from REMAP-CAP and new HIBISCUS trials will tell us more...httPs://www.proactiveinvestors.co.uk/companies/news/932386/faron-pharmaceuticals--explains-the-significance-of-latest-who-solidarity-results-932386.html

[sharesoc] 25/10/2020 13:29

Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020

[sharesoc] 25/10/2020 13:29

Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020

[hashertu] 16/10/2020 15:41

“They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously."
It will be interesting to know whether use of Traumakine continued after the cut-off date for this analysis, or whether any useful information (for Faron) ever becomes available.
A plus for the company is that their prediction (about subcutaneous efficacy) was vindicated.

[latifs100] 16/10/2020 13:52

Faron Pharmaceuticals Oy (LON:FARN) said it was disappointed by results from a study that showed little impact from interferon Beta-1a injected under the skin in halting coronavirus-related deaths. The World Health Organisation's (WHO) Solidarity trial compared 1412 patients who received IFN beta-1a and 2050 control subjects not receiving IFN beta-1a. The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalised patients with COVID-19. Faron’s IFN Beta-1a candidate Traumakine was part of the Solidarity trial, but the company said it only became available very late in the observation period and its understanding was that it had seldom been used. “The WHO has not been able to verify how many patients received Traumakine at the time of this analysis,” said Faron in a statement. About half of the patients receiving IFN beta-1a also received concomitant corticosteroids, which Faron believes hampered the effectiveness of Traumakine in a previous trial. Markku Jalkanen, Faron's CEO, said: "These first results from the Solidarity Trial are disappointing, given the need for new therapeutics to support the global response to COVID-19. “They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously. “The science behind Traumakine and its potential to prevent multi-organ failure, through the upregulation of the key endothelial enzyme CD73, is compelling and we continue to believe that an intravenous formulation of IFN beta-1a is what patients need, to strengthen the body's own IFN beta signalling - the first line of defence against viral infection - and provide optimal exposure to the lung vasculature. "Compared to subcutaneous IFN beta-1a, the same amount of intravenous IFN beta-1a achieves over 150x higher peak concentration in the lung vasculature without higher systemic exposure, which we believe makes this method of administration highly effective and safe. “We will continue to pursue the science behind this." Shares in Faron dropped 21% to 347p.

[toffeeman] 16/10/2020 10:59

This is Farn IV I think

“ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group".

[alexios1201] 16/10/2020 10:48

Seing plenty different opinions...So does it actually work or not???

[toffeeman] 16/10/2020 09:58

Because IV doesn't work in Covid

[latifs100] 16/10/2020 09:51

why the droptoday?

[raldo] 28/9/2020 09:45

Interesting price action today - volume picking up a bit

[jojaken] 25/9/2020 07:10

An interesting write up on Bloomberg about the "increasing evidence (that)suggests that some Covid-19 patients get very ill because of an impaired interferon response". with the likes of the NYT and now Bloomberg picking up on the various studies in journals such as Nature, this can only help to build awareness for the potential of IV-IFN treatments.

[yep1234] 28/8/2020 08:10

hxxps://www.faron.com/news-events/events

hxxps://hcwco.com/transactions/



hxxps://www.meetmax.com/sched/event_61861/conference_home.html?bank_access=0&;event_id=61861

[ih_752952] 24/7/2020 09:24

DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL

Market Cap £38 million
Cash £15 million
Price 30p


Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021

[diversification] 20/7/2020 17:16

They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here?

[tidy 2] 20/7/2020 16:58

To be fair that isnt correct. They answered all the questions and stated for more information you will have to wait for the full report which is more technical and not entirely fit for the laymen in RNS format but the results on the basis of the questions requiring more details the results are positive which will be shown. They stipulated for interferon to be effective in the doses required for Cv19 is has to be inhaled and not injected as it would cause complications due to the concentrate required at the point needed directly in the lungs.

[diversification] 20/7/2020 16:50

I was not at all impressed with the SNG conference call, they couldn’t answer most of the questions as they didn’t have the data to hand.

Let the results tell the story as if it was shown to be ineffective, WHO would it pulled the candidate from the trial in the same way it has with others.

Watch this space.

[tidy 2] 20/7/2020 13:31

Doc on SNG webinar now saying interferon would not be effective injection form.

[bwgs] 20/7/2020 12:50

Bloody hope so!

[soulected] 20/7/2020 11:14

Can't believe how quiet this thread is, everyone must all be over at SNG...Faron's turn next?